Compare General Dynamics Corporation (GD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Tango Therapeutics Inc. — how do they compare? General Dynamics Corporation trades at $338.85 (market cap $89.94B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: General Dynamics Corporation is far larger — about 24× Tango Therapeutics Inc.'s market cap, and General Dynamics Corporation pays a 1.91% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 86 Days and Tango Therapeutics Inc. for 0 Days on average.
| GD | TNGX | |
|---|---|---|
Market Cap | $89.94B | $3.75B |
Volume | 1,284,020 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $395.97 | $32.90 |
52-Week Low | $312.53 | $7.50 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $95.08B | $2.77B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $334.66, down 0.24% with bearish technical signals despite strong fundamentals. The defense contractor shows robust revenue growth, increasing from $47.7B in 2024 to $52.5B in 2025, with consistent earnings beats. Analyst consensus remains bullish with a $414.57 price target, supported by strong Pentagon spending and dividend stability.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.27) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend champion status provide downside protection. Upside potential exists if technical resistance at $337 is breached.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
